Asthma in cystic fibrosis

Journal of the Royal Society of Medicine, Supplement

Volumn 96, Issue 43, 2003, Pages 30-34

  Balfour Lynn, Ian M ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BIIL 284 BS; BRONCHODILATING AGENT; CORTICOSTEROID; CROMLYN; CYCLOSPORIN; FORMOTEROL; IMMUNOGLOBULIN; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ASTHMA; ATOPY; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; HUMAN; INFLAMMATION; LUNG FUNCTION TEST; SIDE EFFECT; SPIROMETRY; SYMPTOM; WHEEZING;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-ANTAGONISTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEUKOTRIENE ANTAGONISTS; LUNG; RESPIRATORY SOUNDS; THEOPHYLLINE;

EID: 0037488592     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Konstan MW, Butler SM, Schidlow DV, et al. for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Patterns of medical practice in cystic fibrosis: Part II. Use of therapies. Pediatr Pulmonol 1999;28:248-54
2. Balfour-Lynn IM, Elborn S. "CF asthma": what is it and what do we do about it? Thorax 2002;57:742-8
3. Morgan WJ, Butler SM, Johnson CA, et al. for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the US and Canada. Pediatr Pulmonol 1999;28:231-41
4. Koch C, McKenzie SG, Kaplowitz H, et al. International practice patterns by age and severity of lung disease in cystic fibrosis: Data from the Epidemiologic Registry of Cystic Fibrosis (ERCF). Pediatr Pulmonol 1997;24:147-54
5. Cooper PJ, Robertson CF, Hudson IL, et al. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol 1990;8:16-22
6. Warner JO, Götz M, Landau LI, et al. Management of asthma: a consensus statement. Arch Dis Child 1989;64:1065-79
7. Brand PLP, van der Ent CK. The practical application and interpretation of simple lung function tests in cystic fibrosis. J R Soc Med 1999;92(suppl 37):2-12
8. Nickerson BG, Lemen RJ, Gerdes CB, et al. Within-subject variability and per cent change for significance for spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis 1980;122:859-68
9. Conway SP, Watson A. Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis. Thorax 1997;52(suppl 2):S64-8
10. Brand PLP. Bronchodilators in cystic fibrosis. J R Soc Med 2000;93(suppl 38):37-9
11. Van Haren EHJ, Lammers J-WJ, Festen J, et al. Bronchial vagal tone and responsiveness to histamine, exercise and bronchodilators in adult patients with cystic fibrosis. Eur Resp J 1992;5:1083-8
12. Sanchez I, Powell RE, Pasterkamp H. Wheezing and airflow obstruction during methacholine challenge in children with cystic fibrosis and in normal children. Am Rev Respir Dis 1993;147:705-9
13. Holzer FJ, Olinsky A, Phelan PD. Variability of airways hyperreactivity and allergy in cystic fibrosis. Arch Dis Child 1981;56:435-9
14. Darga LL, Eason LA, Zach DMS, et al. Cold air provocation of airway hyperreactivity in patients with cystic fibrosis. Pediatr Pulmonol 1986;2:82-8
15. Balfour-Lynn IM. Cardiopulmonary function testing: paediatrics. In: Pryor JA, Prasad SA, eds. Physiotherapy for Respiratory and Cardiac Problems: Children and Adults, 3rd edn. Edinburgh: Harcourt Sciences, 2002:102-26
16. Cypcar D, Lemanske Jr RF. Asthma and exercise. Clin Chest Med 1994;15:351-68
17. Day G, Mearns MB. Bronchial lability in cystic fibrosis. Arch Dis Child 1973;48:355-9
18. Macfarlane PI, Heaf D. Changes in airflow obstruction and oxygen saturation in response to exercise and bronchodilators in cystic fibrosis. Pediatr Pulmonol 1990;8:4-11
19. Marchant JL, Warner JO, Bush A. Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 1994;49:1002-5
20. Warner JO, Kilburn SA. Cystic fibrosis and allergy. Pediatr Allergy Immunol 1996;7(suppl 9):67-9
21. Wilmott RW. The relationship between atopy and cystic fibrosis. Clin Rev Allergy 1991;9:29-46
22. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997;24:137-42
23. Bousquet J, Jeffrey PK, Busse WW, et al. Asthma. From bronchoconstriction to airways inflammation and remodelling. Am J Resp Crit Care Med 2000;161:1720-45
24. Maser C, Kjaergaard S, Pressler T, et al. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. Acta Pathol Microbiol Immunol Scand 2000;108:329-35
25. Skov M, Poulsen LK, Koch C. Increased antigen specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis. Pediatr Pulmonol 1999;27:74-9
26. Heine RG, Button BM, Olinsky A, et al. Gastro-oesophageal reflux in infants under 6 months with cystic fibrosis. Arch Dis Child 1998;78:44-8
27. Ledson MJ, Tran J, Walshaw MJ. Prevalence and mechanisms of gastro-oesophageal reflux in adult cystic fibrosis patients. J R Soc Med 1998;91:7-9
28. Mastella G, Rainisio M, Harms HK, et al. on behalf of the investigators of the Epidemiologic Registry of Cystic Fibrosis. Allergic bronchopulmonary aspergillosis in cystic fibrosis: a European epidemiological study. Eur Resp J 2000;16:464-71
29. Coren ME, Ng V, Rubens M, et al. The value of ultrafast computed tomography in the investigation of pediatric chest disease. Pediatr Pulmonol 1998;26:389-95
30. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998;351:1225-32
31. McCormick A, Fleming D, Charlton J. Morbidity Statistics from General Practice: 4th National Study 1991-2, Series MB5, No. 3 London: HMSO, 1995
32. Kerem E, Reisman J, Corey M, et al. Wheezing in infants with cystic fibrosis: clinical course, pulmonary function, and survival analysis. Pediatrics 1992;90:703-6
33. British guideline on the management of asthma. Thorax 2003;58(suppl 1):1-94
34. Cropp GJ. Effectiveness of bronchodilators in cystic fibrosis. Am J Med 1996;100(suppl 1A):19S-29S
35. Ziebach R, Pietsch-Breitfeld E, Bichler M, et al. Bronchodilatory effects of salbutamol, ipratropium bromide and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatr Pulmonol 2001;31:431-5
36. Spencer DA. Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis. Thorax 1997;52(suppl 2):S89-91
37. Sivan Y, Arce P, Eigen H, et al. A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity. J Allergy Clin Immunol 1990;85:649-54
38. Dezateux C, Walters S, Balfour-Lynn IM. Inhaled corticosteroids for cystic fibrosis. (Cochrane Review.) In: The Cochrane Library. Oxford: Update Software, 2002:issue 3
39. Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323:253-6
40. Bargon J, Viel K, Dauletbaev N, et al. Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients. Eur Resp J 1997;10:2307-11
41. Hordvik NL, Sammut PH, Judy CG, et al. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatr Pulmonol 1999;27:43-53
42. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol 2002;34:287-96
43. Wanner A. Effects of methylxanthines on airway mucociliary function. Am J Med 1985;79:16-21
44. Eber E, Oberwaldner B, Zach MS. Airway obstruction and airway wall instability in cystic fibrosis: the isolated and combined effect of theophylline and sympathomimetics. Pediatr Pulmonol 1988;4:205-12
45. 2 in children with cystic fibrosis. Am Rev Respir Dis 1991;144:1245-9
46. Lammers J-W. Leukotrienes and cystic fibrosis. Clin Exp Allergy Rev 2001;1:175-7
47. 4 concentrations and more severe pulmonary disease. J Allergy Clin Immunol 1994;93:100-7
48. Morice AH, Kastelik JA, Aziz I. Montelukast sodium in cystic fibrosis. Thorax 2001;56:244-5
49. Konstan MW, Walenga RW, Berger M. Prospect of LTB4 receptor antagonism as an anti-inflammatory therapy in CF. Pediatr Pulmonol 2002;34(suppl 24):144-5
50. Eigen H, Rosenstein BJ, FitzSimmons S, et al. and the Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-23
51. Jaffé A, Balfour-Lynn IM. Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids. Paediatric Drugs 2002;4:381-9